Overview
Our Approach
Kearny Funds
Thomas Weisel Partners |
Kearny Venture Partners focuses on investments in the following areas of healthcare: medical devices and drugs (both small molecules and biopharmaceuticals). Our investment strategy is organized around finding and backing transformative companies in these areas, helping them achieve significant inflections in value.
We often identify these transformative companies by prospectively attacking an area of significant unmet need and mapping out key areas of opportunity and risk. Other times, companies are referred to us via an extensive network of advisors and colleagues in industry, academic medicine, and finance.
Inflection points in value occur when critical risks are eliminated. We believe that companies of any age are capable of achieving step changes in value; therefore, we are willing to invest in great companies at many stages. Our investments have ranged from founding companies and formation rounds to later stage investments in well-established companies. Our typical first investment ranges from $2-8 million. Ultimately, we seek to invest $10-15 million per company.
We are often asked if there are particular sectors that we prefer. We believe that important unsolved medical problems exist across many therapeutic areas, and will therefore consider a variety of opportunities with respect to medical disciplines. We also believe in fitting the therapeutic modality to the medical need, and not the other way around. This is one of the reasons that we think it's important to consider both device and drug approaches when examining different clinical problems.
Our partnership has a combined 70 years of healthcare experience across 50 different private companies. In addition to providing capital, we know how private companies create value. After investing, our focus is to help our portfolio companies do exactly that. These activities can be diverse - we have a track record of partnering with our portfolio companies to help build world-class teams, redesign devices, aggregate key intellectual property estates, and reconfigure regulatory strategies. We are also differentiated by our ability to assist our portfolio companies in capturing value by helping position them for an IPO or an acquisition.
|
|
